Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
Study tracks long-term effects of weight loss on atrial fibrillation burden

Study tracks long-term effects of weight loss on atrial fibrillation burden

Patients who receive ablation during mitral valve surgery have less episodes of atrial fibrillation

Patients who receive ablation during mitral valve surgery have less episodes of atrial fibrillation

Cardiome Pharma records net loss of $18.2 million for 2014

Cardiome Pharma records net loss of $18.2 million for 2014

Scientists develop mathematical model to digitally map communication between heart cells

Scientists develop mathematical model to digitally map communication between heart cells

AliveCor launches latest version of AliveECG app

AliveCor launches latest version of AliveECG app

New blood thinner reduces stroke risk in patients with atrial fibrillation

New blood thinner reduces stroke risk in patients with atrial fibrillation

ANI acquires approved ANDA for Flecainide Acetate tablets USP

ANI acquires approved ANDA for Flecainide Acetate tablets USP

New guidelines advise nearly all women, people with AFib to take blood thinners

New guidelines advise nearly all women, people with AFib to take blood thinners

Study demonstrates high compliance among patients using iRhythm's ECG patch monitors to detect AFib

Study demonstrates high compliance among patients using iRhythm's ECG patch monitors to detect AFib

FDA clears AliveCor's automated detectors that record and display ECG rhythm

FDA clears AliveCor's automated detectors that record and display ECG rhythm

VATS lobectomy best for NSCLC patient short-term outcomes

VATS lobectomy best for NSCLC patient short-term outcomes

AliveCor receives CE Mark clearance for algorithm to detect atrial fibrillation

AliveCor receives CE Mark clearance for algorithm to detect atrial fibrillation

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

New analysis finds global improvements in life expectancy

New analysis finds global improvements in life expectancy

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Arrhythmia patients who manage lifestyle factors more likely to have long-term survival

Arrhythmia patients who manage lifestyle factors more likely to have long-term survival

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.